Researches and develops traditional Chinese medicine (TCM) products. Produces a range of TCM products, including granules, finished drugs, and decoction pieces. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 6% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.4× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $769.9M in the vault; even if every debt were paid off, $397.3M would remain.
A loss of $51.1M against $2.2B in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.16. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.